GeNeuro SA

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…

Biotechnology

CH, Plan-les-Ouates [HQ]

Financials

Analysts

Wall Street · Earnings · Institutional Sentiment

A comprehensive analysis section that covers unveiling insights about GeNeuro SA's gradings, price targets and earnings estimates.

Earnings

See the historical earnings and what wall street analysts forecasted and
forecast for future earnings.

Reported

Past Estimate Consensus

Future Estimate Consensus

GeNeuro SA can't present any analysts estimates at the moment detail analysis.

Institutional Sentiment

Wall Street · Earnings · Institutional Sentiment

The institutional sentiment measures the direction of new stock gradings
and price targets while comparing them Year-over-Year. We've limited the grading institutes to those we see as top-tier and update this data every month.

Morgan Stanley

1Y Ago:

n/a

Prev. Grade

n/a

Latest

n/a

JP Morgan Chase

1Y Ago:

n/a

Prev. Grade

n/a

Latest

n/a

Citigroup

1Y Ago:

n/a

Prev. Grade

n/a

Latest

n/a

Overall Consensus

Here we aggregate the price targets and gradings of all IBs/AMCs/Brokerage firms inside our database to draw a bigger picture.

Grading Consensus

Click to each, to see the grade

GeNeuro SA can't present the grade consensus distribution right now.

Price Target Consensus

Price Then

$n/a

Price Target

$n/a

Price Now

$0.07